Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lazertinib DDI Study with Itraconazole and Rifampin
NCT04410094Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of lazertinib in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at 120 hours and Area Under the Plasma Concentration-time Curve at 120 hours. Started Sep 2020; status: completed.
02
Drugs
lazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04410094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04410094.